Literature DB >> 15840764

Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine.

Zachary S Bowman1, Jason D Morrow, David J Jollow, David C McMillan.   

Abstract

Primaquine-induced hemolytic anemia is a toxic side effect that is due to premature splenic sequestration of intact erythrocytes. Previous studies have suggested that a phenolic metabolite, 5-hydroxyprimaquine (5-HPQ), mediates primaquine hemotoxicity by generating reactive oxygen species (ROS) within erythrocytes that overwhelm antioxidant defenses. However, the nature of the oxidative stress is not understood, and the molecular targets, whether protein and/or lipid, are unknown. To investigate the mechanism underlying the hemolytic activity of 5-HPQ, we have examined the effect of hemolytic concentrations of 5-HPQ on ROS formation within rat erythrocytes using the cellular ROS probe, 2',7'-dichlorodihydrofluoresein diacetate. In addition, we examined the effect of 5-HPQ on membrane lipids and cytoskeletal proteins. The data indicate that 5-HPQ causes a prolonged, concentration-dependent generation of ROS within erythrocytes. Interestingly, 5-HPQ-generated ROS was not associated with the onset of lipid peroxidation or an alteration in phosphatidylserine asymmetry. Instead, 5-HPQ induced oxidative injury to the erythrocyte cytoskeleton, as evidenced by changes in the normal electrophoretic pattern of membrane ghost proteins. Immunoblotting with an anti-hemoglobin antibody revealed that these changes were due primarily to the formation of disulfide-linked hemoglobin-skeletal protein adducts. The data suggest that cytoskeletal protein damage, rather than membrane lipid peroxidation or loss of phosphatidylserine asymmetry, underlies the process of removal of erythrocytes exposed to 5-HPQ.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15840764     DOI: 10.1124/jpet.105.086488

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Tafenoquine: A Step toward Malaria Elimination.

Authors:  Kuan-Yi Lu; Emily R Derbyshire
Journal:  Biochemistry       Date:  2020-02-24       Impact factor: 3.162

2.  Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.

Authors:  Jiekun Xuan; Si Chen; Baitang Ning; William H Tolleson; Lei Guo
Journal:  Chem Biol Interact       Date:  2015-10-22       Impact factor: 5.192

3.  An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model.

Authors:  X Jin; B S Pybus; R Marcsisin; T Logan; T L Luong; J Sousa; N Matlock; V Collazo; C Asher; D Carroll; R Olmeda; L A Walker; M P Kozar; V Melendez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06       Impact factor: 2.441

4.  Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers.

Authors:  N P Dhammika Nanayakkara; Babu L Tekwani; H M T Bandara Herath; Rajnish Sahu; Montip Gettayacamin; Anchalee Tungtaeng; Yvonne van Gessel; Paul Baresel; Kristina S Wickham; Marilyn S Bartlett; Frank R Fronczek; Victor Melendez; Colin Ohrt; Gregory A Reichard; James D McChesney; Rosemary Rochford; Larry A Walker
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

5.  Pravastatin provides antioxidant activity and protection of erythrocytes loaded Primaquine.

Authors:  Fars Alanazi
Journal:  Int J Med Sci       Date:  2010-10-28       Impact factor: 3.738

6.  Enantioselective metabolism of primaquine by human CYP2D6.

Authors:  Pius S Fasinu; Babu L Tekwani; N P Dhammika Nanayakkara; Bharathi Avula; H M T Bandara Herath; Yan-Hong Wang; Vijender R Adelli; Mahmoud A Elsohly; Shabana I Khan; Ikhlas A Khan; Brandon S Pybus; Sean R Marcsisin; Gregory A Reichard; James D McChesney; Larry A Walker
Journal:  Malar J       Date:  2014-12-17       Impact factor: 2.979

7.  Mitigation of diazinon-induced cardiovascular and renal dysfunction by gallic acid.

Authors:  Temitayo Olabisi Ajibade; Ademola Adetokunbo Oyagbemi; Temidayo Olutayo Omobowale; Ebunoluwa Racheal Asenuga; Jeremiah Moyinoluwa Afolabi; Adeolu Alex Adedapo
Journal:  Interdiscip Toxicol       Date:  2017-05-17

8.  Insights into biological activity of ureidoamides with primaquine and amino acid moieties.

Authors:  Josipa Vlainić; Ivan Kosalec; Kristina Pavić; Dimitra Hadjipavlou-Litina; Eleni Pontiki; Branka Zorc
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

9.  Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa.

Authors:  Stijn W van Beek; Elin M Svensson; Alfred B Tiono; Joseph Okebe; Umberto D'Alessandro; Bronner P Gonçalves; Teun Bousema; Chris Drakeley; Rob Ter Heine
Journal:  Parasit Vectors       Date:  2021-10-09       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.